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HUB Microfactory - Product-Process Archetype 1: 
continuous crystallisation and crystal engineering coupled with polymer processing steps 
to produce a particle suspension amenable to a range of post-processing e.g. moulding or 
additive-layer printing of solid oral dosage form
Problem statement for Model Drug Mefenamic acid (MFA): Oral bioavailability of 
Mefenamic acid shows significant dependence on particle size leading to variable efficacy. 
Formulation approach: precisely controlled primary particles (D90<42µm) within a 
polymer matrix will deliver optimised physical properties for biopharmaceutics 
performance from a simplified formulation avoiding the need for multiple excipients. 
Deliverables PPA3: improved product manufacturability, simplified formulation with 
consistent dosage form performance, manufactured from a less complex process chain
Target: oral solid dose form with IR release profile at a dose of 250/500mg
Manufacture PPA1: HME – 3DP fused filament fabrication (FFF)/Injection molding
Formulation: crystalline solid dispersion
Predictive approach: 
• Target particle size of D90 = 42 µm was calculated based on the Development 
Classification system (Butler 2010) with a target dose of 250mg. 
• Hansen solubility parameters were determined to identify lowest solubility of  MFA in a 
range of polymers
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Results - HME
MFA – Affinisol 15LV (1:1) was extruded on a Process 11 Parallel Twin Screw 
Extruder at processing temperatures (PT) of 140°C, 150°C, 160°C and 180°C. FTIR 
analysis (Bruker Tensor-II, ATR; Figure 2) and thermal analysis (Netzsch DSC 
Polyma24, Figure 3) of extrudates, physical mixture and MFA showed the 
following properties:
• MFA Form I is stable at ambient temperatures and transforms to Form II via 
sublimation-condensation at elevated temperatures (~172°C): observed for PT 
140°C, 150C°C and PM  
• Extruded MFA-Affinisol 15LV systems exhibit several amorphous (Tg’s) and 
crystalline species (Transition and Tm) within the API-polymer system
• Increasing the HME PT resulted in an increase in amorphous MFA-Affinisol
15LV content seen as a shift of Tg from 127°C to 148°C (not seen in PM )
• Tg of API-polymer system higher than polymer only (~100°C) (MFA non-glass 
former)
• At PT >160C: only crystalline Form in system is Form I 
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Figure 3: Thermogram of extrudates 50% MFA-Affinisol 15LV processed 
at 140°C, 150°C, 160°C, 180°C, Physical mixture (PM) and MFA only.
Tg ~50°
Tg ~127-148°
Tm 
Form II
Transition  I -> II
140C
150C
160C
180C
PM
MFA
Tg ~100° Affinisol
Results – Product performance
MFA is a weak acid with a pKa of 4.2 and a BCS class II 
drug. The dissolution profile is therefore highly 
dependant on particle size and pH.
The dissolution rate was assessed with the Pion Inform 
(Pion Inc) across a range of physiologically relevant pHs
as well as pH 9, the recommended test conditions for QC 
testing (USP 35).  
Two batches with different PSD were prepared by a 
linear cooling crystallisation: Batch 4 with a D90 of 
271um and Batch 1 with a D90 of 64um (wet-milled) 
(Figure 6). The dissolution rate of these MFA powders, 
commercially available MFA powder (Sigma, D90 = 
371um) and a 6mm MFA Sigma powder compact show 
the impact of particle size on dissolution behaviour 
across a pH range of 6.5 - 9 (Figure 4). 
HME extrudates show an improved dissolution 
behaviour across a much wider pH range (pH 2-9, Figure 
5).
Conclusion
The present API-polymer extrudate systems consist of a variety of amorphous and crystalline 
species.  Particle size, presence of polymer and amorphous and crystalline forms impact the 
dissolution behaviour of MFA. 
Next steps
Assessing the impact of amorphous and crystalline forms I and II on 
dissolution behaviour
MFA - Polymer “in-solubility” screening: To increase the crystalline MFA 
content within the API polymer system
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Figure 5: Dissolution MFA-Affinisol extrudate and physical 
mixture versus MFA only compact
Figure 4: Dissolution MFA powder particle size vs compact
Figure 6: Particle size distribution of MFA, Sigma, 
MFA Batch 1 milled, MFA Batch 4
Figure 1: USP II dissolution test (pH 9) of 250mg MFA casules, 
Pharmavit Limited (PVL), Batch 4348
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Figure 2: FTIR spectrum of 50% MFA-Affinisol
extrudates processed at 140°C, 150°C, 160°C, 
180°C, the Physical mixture (PM) and MFA only.
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